五苓散加减治疗中心性浆液性脉络膜视网膜病变临床研究

Clinical Study of Modified Wuling Powder in the Treatment of CSC

  • 摘要: 目的 观察五苓散加减辨证治疗中心性浆液性脉络膜视网膜病变(CSC)的临床疗效。方法 将60例CSC患者随机分为治疗组及对照组各30例。治疗组口服五苓散加减方治疗,对照组口服维生素B1、维生素C治疗。2组均以1月为1个疗程,治疗3个疗程后观察临床疗效。结果 治疗组总有效率为96.7%,对照组总有效率为73.3%,治疗组疗效优于对照组(P<0.05);2组治疗前后视力、FFA荧光渗漏面积及水肿程度比较,P<0.01,治疗组优于对照组(P<0.05)。结论 五苓散加减方治疗CSC有良好疗效。

     

    Abstract: OBJECTIVE To observe the clinical effect of modified Wuling Powder in the treatment of central serous chorioretinopathy(CSC) according to syndrome differentiation. METHODS Sixty patients with CSC were randomly divided into the treatment group and the control group, 30 cases in each group. The treatment group was intervened by orally taking modified Wuling Powder, and the control group was treated with orally taking vitamin B1 tablets and vitamin C tablets, with one course lasting for one month. Clinical effects were observed after 3 courses of treatment. RESULTS The total effective rate in the treatment group was 96.7%, and 73. 3% in the control group. The curative effect was better in the treatment group than that of the control group(P<0.05). Vision, FFA fluorescence leakage area and edema degree were compared before and after treatment to be significantly different in two groups(P<0.01). The treatment group was better than the control group(P<0.05). CONCLUSION Modified Wuling Powder has good curative effects in the treatment of CSC.

     

/

返回文章
返回